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A b s t r a c t  
Preparation and characterization of dual buoyant/mucoadhesive polypropylene microparticles (MPs) 
loaded with Repaglinide (REP) for gastric drug delivery in order to augment the weak mucoadhesion 
in the stomach. 
Porous foam powder MPs were prepared using coating polymers with variable permeability 
(Eudragit L100, Eudragit RSPO) alone or in combination by the soaking method. Thiolated Eudragit 
L100 (Eudragit L100-SH) was also synthesized and tried in an attempt to enhance the 
mucoadhesive properties of MPs. All formulae were characterized for their yield, flow properties, 
particle size, encapsulation efficiency (EE %), morphology, and drug release and its mechanistics. 
Possible interactions inside MPs matrix were also elucidated using FTIR study. The suitability of the 
selected formulae for gastroretention was evaluated by in vitro buoyancy and ex-vivo mucoadhesion 
studies. 
All REP-loaded MPs demonstrated a passable powder flow, high yield values, promising floatation 
and mucoadhesion.Encapsulation efficiency % values were nearly tripled upon addition of Eudragit 
polymers. Compared to the Eudragit free REP loaded foam powder, all formula showed more 
sustained release features.Eudragit L100-SH was synthesized and confirmed by FTIR. Furthermore, 
its incorporation, alone or in combination, exhibited a significant increase in mucoadhesion strength 
compared to the unmodified one. 
Dual buoyant/mucoadhesive MPs loaded with REP encourage planning for future in-vivo 
performance studies for the management of diabetes. 




Various approaches remain the mainstay of successful 
gastroretention, increasing the oral residence of delivery systems 
such as swellable systems, mucoadhesive systems and density 
controlled systems which can be either, high density systems or 
low density (floating) systems[1]. 
Mucoadhesive systems are localized delivery devices in the upper 
gastrointestinal tract, aiming at enhancing the drug absorption 
process. Mucoadhesive polymers, either unmodified or thiolated, 
have the ability to interact with hydrated biological materials, 
retaining dosage forms for a prolonged period of time[2]. 
Compared to unmodified ones, thiolated polymers present an 
effective option, exhibiting strong mucoadhesion and permeation 
enhancing effects worthy of experimentation in gastroretentive 
systems[3].In an attempt to develop mucoadhesive system based 
on thiolated polymers, Bravo-Osuna et al. prepared coated 
poly(isobutyl cyanoacrylates) nanoparticles witheither chitosan or  
thiolated chitosan. The authors evaluated their mucoadhesion 
properties using rat intestinal mucosal surfaces. The abundance of 
thiol groups on the surface of nanoparticles were found to increase 
the mucoadhesion of such formulae by forming disulfide linkages 
with the cysteine residues of mucous membranes[4]. 
However, effective mucoadhesive systems are challenging since 
the bond formation between mucoadhesive polymer and mucus is 
dramatically reduced by the acidic environment present in the 
stomach[5]. Moreover, high turnover rate of the gastric mucus 
renders the retention of mucoadhesive system in stomach very 
difficult [6]. 
Floating drug delivery systems, as another gastroretention 
mechanism, receive extensive attention owing to their promising 
buoyant potential. Inherent low density of floating drug delivery 
systems can be provided by the incorporation of low density 
materials, such as fatty substances or oils [7], or by entrapment of 
air in porous materials which imparts low density for such material 
and result in their buoyancy. Several research groups have 
investigated the use of low density macroporous polypropylene 
foam powder [8, 9]and silicates [10] carriers. Such porous carriers 
are effective in terms of facilitating the incorporation of drugs inside 
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controlling polymers, in particular, Eudragit® copolymers. Despite 
of the coating process, the polymers partially cover the pores and 
trap air within the coated system. The trapped air in the coated 
formulation is gradually removed from the system leading to 
extended floating times[11]. In a study conducted by Streubel et al., 
floating MPs based on low-density foam powder were successfully 
prepared using oil-in-water solvent extraction/evaporation method 
and their in vitro performance was tested [8]. Eudragit® RS, ethyl 
cellulose and polymethyl methacrylate (PMMA) were also used as 
release controlling polymeric coats. The MPs possessed good in 
vitro floating behavior and drug release was found to be affected by 
drug loading, polymer type and amount. 
In this respect, combined floating, based on macroporous foam 
powder, with mucoadhesion mechanisms were designed in this 
study to enhance the gastroretentive potential of matrices and 
avoid the premature loss of the system by mucous turn over. 
Based on their extensive incorporation in controlled release 
gastroretentive matrices [12], Eudragit polymers are employed in 
this work. Eudragit L100 and RSPO polymers are chosen as 
reservoirs, giving a possible chance for release of drug over a 
specific period of time at a predetermined and controlled rate. 
Eudragit L100 is an anionic copolymer based on methacrylic acid 
and methyl methacrylate with the ratio of the free carboxyl groups 
to the ester groups is approx. 1:1.  Its solubility was revealed above 
pH 6 medium, resulting in effective controlled release and variable 
drug release profiles [13]. Eudragit RSPO is a insoluble copolymer 
of ethyl acrylate, methyl methacrylate and a low content of 
methacrylic acid ester with quaternary ammonium groups, 
possessing low permeability and pH independent swelling 
characteristics [14]. 
Thiolated EudragitL100 (Eudragit L100-SH) as a thiomer was also 
utilized, aiming at optimally achieving improved mucoadhesive 
features. Eudragit L100-cysteine conjugate was synthesized by 
forming covalent bonds between the amino groups of the cysteine 
and the carboxylic groups of the Eudragit L100 moreover, 
formation of disulfide bridges between the thiolated polymers and 
cysteine-rich subdomains of glycoproteins secretions in the 
biosystems mimic the natural anchoring of mucus glycoproteins in 
the mucus layer[15]. 
Repaglinide (REP), a carbamoyl methyl benzoic acid derivative 
which act by enhancing as insulin secretion in a manner similar to 
glucose stimulation in the human body. The drug is capable of 
controlling blood glucose level, and minimize macro and 
microvascular complications associated with diabetes. REP is only 
available as conventionaloral tablets, however, REP suffers from 
poor absorption in the upper intestinal tract , low bioavailability 
(50%) and short plasma half-life (<1hr) [16]. The use of 
mucoadhesive floating REP delivery system would enhance its 
gastroretention, and improve drug bioavailability.  
The goal of this study was to encapsulate REP in polypropylene 
foam powder MPs, comprising Eudragit L100, RSPO and thiolated 
Eudragit L100polymers. All formulations were evaluated by yield, 
powder flowability, particle size, encapsulation efficiency, drug 
release and FTIR. Surface characteristics and morphology of MPs 
were investigated using scanning electron microscopy (SEM). In 
vitro floating behavior was performed in 0.1N HCl. The MPs 
mucoadhesive potential was also tested using ex-vivo model. 
Materials and methods 
 
Materials 
Polypropylene foam powder (Accurel® MP1000) was purchased 
from Membrana GmbH, Obermburg, Germany.  Repaglinide (REP) 
was supplied as a gift from EPICO Pharmaceuticals, Egypt. 
Eudragit L100 and RSPO were purchased from Evonik Pharma, 
GmbH, Darmstadt, Germany. Ethanol, hydrochloric acid and 
sodium hydroxide pellets were of analytical grade and purchased 
fromEl Nasr pharmaceutical Co., Cairo, Egypt. Dimethyl sulfoxide 
(DMSO), N,N-dicyclohexylcarbodiimide (DCC), N-hydroxyl 
succinimide (NHS), l-cysteine hydrochloride were purchased from 
Sigma Chemical Co., St. Louis, US. 
Preparation of thiolated EudragitL100 (Eudragit L100-
SH) 
Eudragit L100-SHwas synthesized according to method reported 
previously [15]. Briefly, Eudragit L100solution in dimethyl sulfoxide 
(DMSO) was prepared thenN,N-dicyclohexylcarbodiimide(DCC) 
and N-hydroxyl succinimide (NHS) were added before l-cysteine 
hydrochloride was dissolved in smallest amount of DMSO and 
added to reaction mixture. Reaction was left at room temperature 
under nitrogen environment then it was stopped by the removal of 
unbound l-cysteine hydrochloride by dialysis against DMSO 
initially, and then against distilled water. After dialysis, the polymer 
solution was freeze-dried and the conjugate was stored in air tight 
containers at 4 ◦C until further use. 
Preparation of MPs (F1-6) 
REP-loaded polypropylene foam powder formulations (F1-6) were 
prepared using soaking technique[9, 17].MPs were prepared by 
first dissolving REP and polymer(s) (Eudragit L100, Eudragit RSPO 
or Eudragit L100-SH) in ethanol then polypropylene foam powder 
(physically separated fraction between 25 and 50 Mesh) was 
dispersed in the ethanolic solution and the resulting suspension 
was poured into Teflon trays. The drug was allowed to adsorb into 
the MPs porous structure and onto their surface as ethanol was let 
to evaporate at room temperature. MPs were removed from trays, 
dried in desiccator and free-flowing MPs were obtained. Six 
formulations were prepared, keeping the amount of the drug, ratio 
between polymer and foam powder constant (at ratio of 1:1) while 
varying the polymer type. The compositions of various formulae 
were given in Table 1. 
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Table1: Composition of REP-loaded macroporous foam powder MPs. 
  Formula code   
F1 F2 F3 F4 F5 F6 
Foam powder 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 
REP 10 mg 10 mg 10 mg 10 mg 10 mg 10 mg 
Eudragit L100  100 mg  50 mg   
Eudragit RSPO   100 mg 50 mg  50 mg 
Eudragit L100-SH     100 mg 50 mg 
 
MPs characterization 
MPs yield  
The MPs yield values were calculated by gravimetry, comparing 
the initial total solid (drug, foam powder and polymer) with the 
resultant powder amount after the formation MPs 
Powder flowability 
The fixed height cone method was adopted. In this method, a glass 
funnel with an internal diameter of 3 mm was tightened at 1 cm 
height. The spray dried powder was allowed to flow at a constant 
rate through the funnel orifice till the apex of the formed cone 
reached the funnel stem. The powder flow was stopped and the 
diameter of the base of the formed cone was measured. The angle 
of repose was calculated as follows: 
D
h2
tan                                     (1) 
Where:  ɵ is the angle of repose, h is the height of the cone and D 
is the diameter of the base of the formed cone. The test was 
repeated five times for each run and the average value was taken. 
Values for the angle of repose below 25 indicate excellent flow, 25-
30 good flow, 30-40 passable flow while those above 40 denote 
very poor flow. 
REP-loaded MPs encapsulation efficiency (EE %)  
Samples (5 mg) of REP-loaded MPs were soaked in 5mL of 
ethanol. The obtained solution was stirred for 12 hr then filtered. 
Drug content was determined by UV spectrophotometry(UV-
1601,Shimadzu) at predetermined λmax= 240nmand the drug 




EE            (2) 
Morphological examination 
The morphological characteristics of REP- loaded MPs were 
examined by scanning electron microscopy (SEM) (JEOL 5500, 
Tokyo, Japan). A small amount of powder was spread on an 
aluminum stub and, after gold sputtering, was visualized at 20 kV 
acceleration voltages under argon atmosphere and images were 
obtained.The porous morphology of foam powder and F5 particles 
were also visualized using optical microscope(Carl Zeiss, Berlin, 
Germany) and photographed at a magnification of 100X by means 
of a fitted camera (Panasonic, Japan) for morphological evaluation, 
as a confirmatory tool for the partial coating process. 
Particle size (PS) determination  
The size of REP-loaded polypropylene microparticles (F1-6) was 
estimated using optical microscope images taken by binocular 
optical microscope Ziess Axiolab A. Images were then analyzed 
using Image J software package version 1.49 to measure the 
Feret`s diameter of microparticles and mean values(n>40) were 
calculated (mean Feret’s diameter is the distance between two 
parallel and opposite tangent lines to the particle profile in different 
directions). 
In-vitro drug release 
A suitable amount of MPs equivalent to 1mg REP were added to 
10 mL of 0.1 N HCl (pH 1.2) in closed vials shaken at 75 rpm/ min 
in an incubator (GFL Shaker, LABOTEC, Germany) maintained at 
37 ± 0.5 °C. At specified time intervals (15, 30, 60, 120, 180, 240, 
300, 360, 420, 480 minutes), 0.5mLsamples were removed and 
replaced with fresh 0.1 N HCl. The samples were centrifuged, 
properly diluted if required and analyzed spectrophotometrically at 
predetermined λmax=240 nm to determine drug concentration.  
In-vitro release profiles were analyzed using different kinetic 
models(zero order, first order, and Higuchi’s model), and the 
release mechanism was determined using Korsmeyer-Peppas 
model[18]. 
Fourier transform Infrared (FTIR) spectroscopy 
FTIR spectra of REP, foam powder, EudragitL100, Eudragit RSPO 
or Eudragit L100-SHand REP loaded MPs were recorded with an 
FTIR spectrometer using KBr disc method. Each sample was 
gently triturated with KBr powder in a weight ratio of 1:100 and then 
pressed using a hydrostatic press at a pressure of 10 tons for 5 
min. The disc was then placed in the sample holder and scanned 
from 4000 to 400 cm-1. All spectra were recorded at ambient 
temperature under vacuum to remove air humidity contribution at a 
resolution of 4 cm-1 and 16 times scanning for each measurement 
to obtain an adequate signal to-noise ratio. 
Percentage buoyancy of MPs  
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Floating behavior studies were performed by placing 60 particles 
into beakers containing preheated (at 37 °C)30 mL 0.1 N HCl pH 
1.2, containing 0.02% w/v Tween 20 to exclude floating due to non-
wetted surfaces, followed by horizontal shaking (37 °C, 75 rpm). At 
predetermined time intervals, the beakers were allowed to stand for 
5 min without agitation and the number of settled particles was 
counted then subtracted from the total number of particles and 
buoyancy was expressed as percentage particles remain floating at 
certain time interval [8].The floating behavior of polypropylene foam 
powder as received and some representative examples of formulae 
was inspected visually as well. 
Ex-vivo  mucoadhesive strength determination 
Mucoadhesion studies of formulations were carried out using 
Texture Analyzer CT3 (Brookfield Engineering Laboratories, Inc., 
Middleboro, US). Freshly excised rat intestinal mucosa was used. 
The mucosal tissue was cut in small pieces and attached to the 
probe (stainless steel cylindrical probe with 10 mm diameter). The 
moistened formulations were held on the lower plate. The probe 
was lowered at a speed of 3 mm/s until the formulation made 
contact with mucosal tissue. A constant force of 3 N was applied 
for 3 min[19], after which the probe was withdrawn at a speed of 3 
mm/s to a distance of 20 mm. Work of adhesion (mJ) was 
calculated from force-distance plot using Texture Exponent 
software package of the instrument. Each experiment was carried 
out in triplicate. Gross morphological evaluation of mucoadhesive 
potential of representative F1 and F5 was assessed as well. The 
freshly excised rat intestines were examined macroscopically for 
the ability of MPs to adhere to the mucosal surface. 
Statistical analysis 
Data are expressed as mean of three determinations ± standard 
deviation. Comparison of the mean values was performed using 
either Student’s t-test or ANOVA (analysis of variance) using 
GraphPad In Stat software program. Statistical significance was set 
at P-value ≤ 0.05.  
Results and discussion 
In the present investigation, REP-loaded macroporous 
polypropylene foam powder MPs were prepared by soaking 
technique. EudragitL100, EudragitRSPOandEudragitL100-SHwere 
used as release retarding polymeric materials. Polymers were used 
separately or in combination to prepare different formulae using 
ethanol as solvent for dissolving controlled release polymers. The 
MPs prepared were further evaluated for various physical 
parameters such as yield, angle of repose, particle size, and 
encapsulation efficiency. In-vitro dissolution studies were carried 
out on all the formulae employing 0.1N HCl (pH 1.2) as dissolution 
medium. In-vitro floating behavior and ex-vivo mucoadhesion 
studies were also performed to assess tested formulation 
gastroretentive potential. 
MPs characterization 
The physical parameters evaluated for various MPs were given in 
Table 2.The % yield values of MPs prepared by soaking technique 
was found to be in the range of 71.39-88.23%.All formulations 
showed passable flowability as expressed in terms of angle of 
repose ranging from 30.25 – 38.52 deg. This suggests that such 
MPs are ideal candidates for direct compression into tablets and 
that the floating microparticles produced are non-aggregating. 
The mean Feret`s diameter measured by microscopy was found to 
be in the range of412.73- 564.62 µm with no significant difference 
between the tested non coated formula F1 and Eudragit coated 
formulae (F2-6). This means that using coating polymers did not 
affect particle size and this may be due to the small thickness of 
drug/polymeric coats on foam powder surface as seen in Figure 1. 
REP-loaded MPs encapsulation efficiency (EE %)  
The values of encapsulation efficiency % of entrapped REP inside 
the porous compartment of prepared MPs was found to be in the 
range of 39.75-58.29%. REP-loaded foam powder(F1) showed 
high EE% reaching 54.91%. Addition of polymers did not 
significantly (p<0.05) affect the proportions of REP incorporated. 
The interaction between the positively charged Eudragit RSPO and 
the acid carboxyl group in REP might have occurred, forming 
molecular complexes that will increase REP solubility[20]. This 
increase in drug solubility will result in hindering the drug to be 
incorporated into the macroporous microparticles during solvent 
evaporation step leading to the slight decrease in EE% values that 
was noticed with foam powder formulae containing Eudragit RSPO 
(F3, F4and F6)(Table 2).  
 
Table 2: Characterization of REP-loaded macroporous foam powder MPs. 
Formula code % yield ± SD Angle of repose ± SD FD* ± SD EE% ± SD n value Release mechanism 
F1 77.40 ± 0.32 38.52± 1.23 564.62± 111.52 54.91 ± 10.53 0.411 Fickian 
F2 74.58 ± 0.31 36.61± 1.07 484.67± 104.37 58.29 ± 19.21 0.548 Non-Fickian 
F3 72.48 ± 0.36 38.17± 0.82 412.73±106.39 39.75 ± 11.2 0.419 Fickian 
F4 88.23 ± 0.24 32.60± 0.81 471.54± 142.93 48.24 ± 6.96 0.886 Non-Fickian 
F5 71.39 ± 0.45 30.25± 0.65 501± 118.07 53.68 ± 4.01 0.507 Non-Fickian 
F6 77.32 ± 0.19 30.35± 2.49 419.32± 116.23 50.55 ± 7.98 0.519 Non-Fickian 
  *FD is Feret diameter measured from optical microscope images 








Accurel MP1000 is a polypropylene microparticles which have low 
density due to the macroporous nature of such microparticles with 
pore size in the range of 5 to 20 μm[21].  
SEM imaging of F1-6 showed that all dry formulae were irregular in 
shape and non-fused[8, 17] and they also possess highly porous 
structure with pores of almost similar size to those recorded on 
foam powder substrate surface. As shown in Figure 1, the porous 
system of polypropylene foam powder was mostly in the 
macroporous range and  pores can be seen to be either totally or 
partially covered with either drug (Figure 1A) or drug/ polymer 
(Figure 1B-F). The deposits formed can be on both molecular level 
and as precipitates. During the preparation of different formulae 
and as the solvent evaporate, the drug initially adsorbed on 
substrate surface then precipitated within its porous system[22].  
Optical microscope imaging was also consistent with SEM data 
where the porous nature of F1 was confirmed, showing an outer 
layer with lighter color and a distinct dark interior of the MP marked 
by the drawn red line in its perimeter (Figure1G). Although the 
inner core is porous; the high opacity shown in the image is due to 
the strong light scattering in the core which has higher thickness 
compared to the outer layers. Moreover, the coating of foam 
powder particles with drug/polymer deposits adhering to foam 
powder surface as thin sheets can be occasionally seen  as 
denoted by the white arrow in both SEM image of F2 (Figure 1B) 




Figure 1: SEM images of REP-loaded MPs of (A) F1 (white arrow show drug/polymer coat), (B) F2, (C) F3, (D) F4, (E) F5 and (F) F6 (white bar 
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In-vitro drug release and release kinetics 
In-vitro release profiles of REP from the prepared REP-loaded MPs 
were determined at various times intervals are shown inFigure2. 
The amount of REP released in 8 h from different MPs (Q8h) was 
used for comparison. F1 which is the product of solvent deposition 
of REP on foam powder showed the highest release rate when 
compared to F2-6 (p<0.001) with a value of 58.31% REP being 
dissolved after8 hrs. This would confirm that mixing REP with 
polyacrylate polymers would sustain its release. Moreover, 
depositing REP with coating polymers into the pore system and on 
the surface foam powder MPs led to a sustained pattern of drug 
release over 480 min depending on the polymer type and 
composition and with no observed burst release in any of these 
formulae (F2-6). It is worth noting that MPs retained their integrity 
during release study, owing to their composition of polypropylene 
foam powder[8] and acrylic polymers [23] which are insoluble in 
acidic release medium.  It was also found thatQ8hvalues of the MPs 
were in the range of 13.87-40.27%. On one hand, F2 and F4 
exhibited the lowest release profile among all the formulae with no 
significant difference between Q8h values of the two formulae 
(p>0.05).  This suggests the negative influence of the addition of 
Eudragit L100 alone or in combination with Eudragit RSPO to foam 
powder particles on REP release. Such markedly suppressed 
release of REP might be attributed to the pH dependent solubility 
of Eudragit L100 which do not allow for REP molecules to escape 
to release medium until MPs are exposed to higher pH values. At 
high pH only, the carboxylic groups of Eudragit L100 become 
progressively ionized and hydrated, causing particles to swell as an 
initial prerequisite for drug release. This finding was in agreement 
with that reported previously for similar systems coated with pH 
sensitive Eudragit and its derivatives [3, 24, 25]. The slight 
solubility of REP in low pH render coating polymer solubility to be 
the limiting factor for drug release [10]. As for F4, decreasing the 
amount of Eudragit L100 by blending with the swellable Eudragit 
RSPO fails in increasing the drug release a little higher (p>0.05). 
On the other hand, significantly higher Q8h values were noticed 
with F3 (MPs containing Eudragit RSPO), F5 (MPs containing 
Eudragit L100-SH) and F6 (MPs containing blend of Eudragit L100-
SH  and Eudragit RSPO) amounting to 40.27, 33.36 and 25.57 % 
respectively (p<0.05). This could be probably due to the higher 
permeability of these MPs to the surrounding dissolution medium 
owing to their content of Eudragit RSPO and mucoadhesive 
Eudragit L100-SH.However, statistical analysis revealed non 
significant difference in Q8h forF3 and F5 (p> 0.05), confirming the 
superiority of these two polymers in modulating drug release. 
A Higuchi model was found to describe REP-loaded MPs release 
kinetics, showing the highest R2 values (0.9882-0.9986) amongst 
zero and first order release kinetics. This indicates that diffusion 
through matrices was the main factor controlling REP release. 
The dissolution data were fitted according to the exponential 
Korsemeyer-Peppas Equation [26]and the calculated exponent n 
values were listed in Table 2. Peppas model gave a good fit to 
most of the dissolution data of the formulae as shown by the R² 
values (0.9939 - 0.9993). While the majority of formulae exhibited 
Fickian or near Fickian release behavior with n value around 0.5, 
non-Fickian release mechanism (0.886) was seen with F4 
(containing Eudragit L100-Eudragit RSPO combination)[27]. 
Based on in-vitro drug release results, controlled REP release 
pattern might provide us an idea about the effect of REP interaction 
inside MPs matrices on its release pattern. FTIR has always been 
proven a good confirmatory tool in this respect. 
 
 
Figure2: Release profiles of REPloaded foam powder F1-F6 in 0.1 N HCl at 37°C. 
 
Fourier Transform Infrared Spectroscopy (FTIR) The FTIR spectra of the starting materials and MPs formulae are 
presented in Figure3.REP spectrum, illustrated in Figure3, shows: 
a strong absorption peaks at 3307.5 cm-1 assigned to N-H 
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stretching vibration, a C-H stretching band at 2984.1 cm-1, carbonyl 
group band at 1687.6  cm-1 and  bands at 1445.0 and 1215.5 cm-1 
resulting from C-O stretching and O-H bending vibrations [28].  
The Eudragit L100 polymer contains both carboxylic acid and ester 
groups. In Eudragit L100 FTIR spectrum, several characteristic 
absorbance peaks could be identified: strongly associated OH 
vibrations were recorded at 3509.4 and 3233.9 cm-1, peaks at 
2997.8 and 2953.6 cm-1  assigned to CH vibrations, and 
characteristic peaks at 1726.1and 1449.5 cm−1was attributed to  
carbonyl vibrations of the ester group and C–O bond stretching 
respectively[29].Similar FTIR spectrum of Eudragit L100-SHwas 
observed, however,  anew absorption band at 1549.8 cm-1 was 
noticed in Eudragit L100-SHFTIR spectrum indicative of the 
sulphydryl groups confirming the formation of Eudragit L-100–
cysteine conjugate [30].Moreover, a shift to a higher wave number 
(+25 cm-1) was observed for the hydroxyl part (OH) peaks of 
carboxylic group in Eudragit L100-SH. This O-H shift might predict 
the possible formation of intramolecular hydrogen bonding between 
hydroxyl groups of the polymer and sulfhydryl group[15]. 
Eudragit® RSPO spectrum shows the characteristic bands of the 
ester groups at 1147.0 cm-1 and 1242.0cm-1as well as the C=O 
ester vibration at 1729.2cm-1[31]. In addition, absorption peak at 
3439.2 cm-1 assigned to N-H stretching vibration and a C-H 
stretching bands at 2992.4 – 2954.0 cm-1 were recorded too.  
In  polypropylene foam powder FTIR spectrum, The CH3 bands 
were recorded at 2958.1 cm-1, 2872.7 cm-1and 1377.1 cm-1and 
peaks at 2839.0 cm-1and 1459.0 cm-1assigned to the CH2 bands 
[32]. 
FTIR spectrum of all formulae F1-6 showed that the characteristic 
N-H stretching vibration peak of REP at 3,307.5 cm-1disappeared 
together with many other drug characteristic peaks in REP-loaded 
MPs, indicating the presence of a strong interaction between REP 
and MPs matrix. Changing the foam powder MPs matrix by 
incorporation of polymers with variable permeability and their 
blends resulted in formation of molecular interactions which may 
have implications on drug release characteristics. This might be at 




Figure3: FTIR spectra of a) REP, b) Eudragit L100, c) Eudragit RSPO, d) Eudragit L100-SH, e) foam powder and f-k)F1-6 respectively. 
 
Percentage Buoyancy of MPs 
Figure4 shows the percentage of floating MPs versus time. 
Immediate in-vitro floatation and extended floating times (up to at 
least 8 hr) were observed in all formulae. This is due to the highly 
porous structure as noticed in SEM micrographs. Thus, the porous 
nature of MPs could produce an upward motion of the dosage form 
to float on the gastric contents[8].  
Buoyancy % values varied considerably among formulae, ranging 
from 54.44 to 95.55% and were dependent on formulae 
composition. 
Uncoated REP-loaded foam powder (F1), as a control, showed the 
highest floatability (95.55%). The foam powder particles have a 
highly porous structure as noticed in SEM micrographs. The 
addition of polymers to foam powder particles significantly affected 
the floating behavior of the MPs. As said previously, the partial 
coverage of foam powder surfaces by the polymers might be at the 
base of the observed lower buoyancy values. However, the 
entrapped air within the system guaranteed their instantaneous 
floating. In addition, upon exposure to aqueous media, the 
entrapped air is slowly removed from the system leading to 
extended floating times (Figure5). 
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Moreover, the nature of the polymer influenced the floating 
behavior of the MPs. Buoyancy percentage of MPs containing 
Eudragit L100 (F2) was significantly higher than that of MPs 
containing Eudragit RSPO (F3) and their combination (F4). It was 
evident that Eudragit RSPO increased the permeability of MPs to 
the surrounding dissolution medium and hence, their hydration due 
to the swelling nature of the polymer. Consequently, their hydration 
replaced the air inside the floating MPs, thus rendering them less 
buoyant. 
Moreover, MPs containing Eudragit L100-SH alone or in 
combination with Eudragit RSPO were least buoyant (formulae F5 
and F6). It is likely that the thiolated polymers incorporated in the 
formulations would have increased their wettability and increased 
amount of absorbed liquid medium as compared to unmodified 
polymer. Despite of these findings, satisfactory and acceptable 
floatation was achieved in all formulae when compared to what 
was reported earlier[23, 33, 34].Figure 5 shows the floating 
behavior of foam powder, F1 and F5 as observed visually, however 
only F5 containing Eudragit L100-SH show not only floatation but 
also adhesivety to container wall. 
 
 
Figure4: Percentage buoyancy of REP-loaded foam powder MPs F1-F6. 
 
Figure 5: Floating behavior of (A):foam powder, (B): F1 and (C) F5. 
 
Ex-vivo mucoadhesive Strength Determination 
When considering gastroretention, it is highly desirable to formulate 
the MPs with mucoadhesive materials to enhance their retention 
time in the gastric cavity, thus, improving drug bioavailability[3]. 
Mucoadhesion test was performed to measure the MPs adhesive 
strength using a texture analyzer. The measured values for work of 
mucoadhesion of all formulae as presented in Figure6. MP scan be 
ranked according to their mucoadhesiveness as follows: F5 > F6 > 
F4 > F2 > F3. F5 containing Eudragit L100-SHwas superior in 
terms of mucoadhesive strength, exhibiting a significant 1.56 to 
3.56 fold increase in work of adhesion values compared to F2 and 
F6 respectively( p< 0.05).Statistical analysis also revealed no 
significant difference between F2, F3 and F4 ( p> 0.05). The 
introduction of sulphydryl groups to Eudragit L100-SH might be at 
the base for such improvement in Eudragit L100-SH containing 
MPs. The sulphydryl group can form a disulphide bonds with the 
mucus glycoprotein, which is supposed to be responsible for the 
enhanced mucoadhesive properties [35]. Interestingly, the 
adhesive nature of F5 was also evident while performing buoyancy 
test Figure 5 (C) and in the sectioned intestine (see Figure6).Upon 
comparing thiolated polymer with unmodified Eudragit L100 (F2) or 
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decreasing its content by combining it with Eudragit RSPO (F6) 
resulted in significantly lower values of the work of adhesion. 
Moreover, although values of work of adhesion were higher for 
MPs containing Eudragit L100-Eudragit RSPO combination (F4) as 
compared to F2 and F3, however no significant difference was 
found between these formulae. 
 
 
Figure6: Work of adhesion of REP-loaded foam powder MPs F1-F6. In the top photographs for gross appearance of sectioned intestine a) 
control b) with mucoadhesive formula F5. 
 
Conclusion 
REP-loaded macroporous matrices were successfully prepared 
and their suitability for gastric retention was demonstrated in terms 
of in-vitro buoyancy and ex-vivo mucoadhesion. Due to its 
interaction with positively charged Eudragit RSPO to form 
molecular complexes highly soluble in ethanol, REP was 
moderately entrapped inside pores of foam powder formulae 
coated with such polymer. Type of coating polymers and their 
blends greatly influenced the drug release, kinetics of release data, 
floatation and mucoadhesion. All Formulae were able to sustain 
drug release over 8hr.The in-vitro and ex-vivo experiments 
assessed their gastroretentive potential, proving their usefulness 
as controlled delivery systems. Such promising findings encourage 
planning for future studies to give evidence of in-vivo performance 
of these matrices for the management of diabetes. 
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